The Impact Of Customer Satisfaction On Chief Marketing Officers Compensation

As an intangible marketing asset, customer satisfaction is rarely apparent on financial statements. The contribution of customer satisfaction on firm financial performance is well documented, but it is unclear whether this positive link is reflected in executive compensation. Besides, executives are often compensated for short-term financial results but the outcome of marketing actions is rarely captured in a short horizon. This research seeks to determine if the compensation of Chief Marketing Officers (CMO), who is primarily responsible for marketing outcome, is impacted by customer satisfaction. We find that customer satisfaction has a significantly positive impact on the total cash compensation of CMO and its cash and bonus components when controlling for firm performance, firm size, and innovation. Overall, our results support the inclusion of nonfinancial performance measures, specifically customer satisfaction, in designing senior marketing executive compensation packages

Immunotherapy Targets in Pediatric Cancer

Immunotherapy for cancer has shown increasing success and there is ample evidence to expect that progress gleaned in immune targeting of adult cancers can be translated to pediatric oncology. This manuscript reviews principles that guide selection of targets for immunotherapy of cancer, emphasizing the similarities and distinctions between oncogene-inhibition targets and immune targets. It follows with a detailed review of molecules expressed by pediatric tumors that are already under study as immune targets or are good candidates for future studies of immune targeting. Distinctions are made between cell surface antigens that can be targeted in an MHC independent manner using antibodies, antibody derivatives, or chimeric antigen receptors versus intracellular antigens which must be targeted with MHC restricted T cell therapies. Among the most advanced immune targets for childhood cancer are CD19 and CD22 on hematologic malignancies, GD2 on solid tumors, and NY-ESO-1 expressed by a majority of synovial sarcomas, but several other molecules reviewed here also have properties which suggest that they too could serve as effective targets for immunotherapy of childhood cancer

Molecular Alterations in Pediatric Sarcomas: Potential Targets for Immunotherapy

Purpose/results/discussion. Recurrent chromosomal translocations are common features of many human malignancies. While such translocations often serve as diagnostic markers, molecular analysis of these breakpoint regions and the characterization of the affected genes is leading to a greater understanding of the causal role such translocations play in malignant transformation. A common theme that is emerging from the study of tumor-associated translocations is the generation of chimeric genes that, when expressed, frequently retain many of the functional properties of the wild-type genes from which they originated. Sarcomas, in particular, harbor chimeric genes that are often derived from transcription factors, suggesting that the resulting chimeric transcription factors contribute to tumorigenesis. The tumor-specific expression of the fusion proteins make them likely candidates for tumor-associated antigens (TAA) and are thus of interest in the development of new therapies. The focus of this review will be on the translocation events associated with Ewing's sarcomas/PNETs (ES), alveolar rhabdomyosarcoma (ARMS), malignant melanoma of soft parts (MMSP) (clear cell sarcoma), desmoplastic small round cell tumor (DSRCT), synovial sarcoma (SS), and liposarcoma (LS), and the potential for targeting the resulting chimeric proteins in novel immunotherapies

RMCE-ASAP: a gene targeting method for ES and somatic cells to accelerate phenotype analyses

In recent years, tremendous insight has been gained on p53 regulation by targeting mutations at the p53 locus using homologous recombination in ES cells to generate mutant mice. Although informative, this approach is inefficient, slow and expensive. To facilitate targeting at the p53 locus, we developed an improved Recombinase-Mediated Cassette Exchange (RMCE) method. Our approach enables efficient targeting in ES cells to facilitate the production of mutant mice. But more importantly, the approach was Adapted for targeting in Somatic cells to Accelerate Phenotyping (RMCE-ASAP). We provide proof-of-concept for this at the p53 locus, by showing efficient targeting in fibroblasts, and rapid phenotypic read-out of a recessive mutation after a single exchange. RMCE-ASAP combines inverted heterologous recombinase target sites, a positive/negative selection marker that preserves the germline capacity of ES cells, and the power of mouse genetics. These general principles should make RMCE-ASAP applicable to any locus

Intimate Partner Violence and COVID-19 in Rural, Remote, and Northern Canada: Relationship, Vulnerability and Risk

In rural, remote, and northern parts of Canada, the pre-existing vulnerability and risk for intimate partner violence has been exacerbated by COVID-19. The purpose of this commentary is to identify the unique impact of COVID-19 on intimate partner violence both in terms of the bearing on those experiencing abuse and on the service sector in rural, remote and northern communities where the rates of intimate partner violence and intimate partner femicide pre-pandemic are higher than in larger cities. The recommendations offered in this paper include enhanced safety planning, alternate housing for victims fleeing violence, and suggestions for service providers. We also offer ways to move forward with further research in the COVID-19 era

The efficacy of bariatric surgery performed in the public sector for obese patients with comorbid conditions

Objective: To determine the effi cacy of bariatric surgery in the public sector for the treatment of complicated obesity. Design, setting and participants: A longitudinal observational study of obese participants with comorbid conditions, aged 21-73 years, who underwent publicly funded bariatric surgery. Data were extracted from clinical databases (1 October 2009 to 1 September 2013) and recorded at seven time points. Participants are from an ongoing public obesity program. Main outcome measures: Postoperative weight loss and partial or full resolution of: type 2 diabetes mellitus (T2DM), hypertension (HTN), dyslipidaemia and obstructive sleep apnoea (OSA). Results: The 65 participants in the cohort lost a mean weight of 22.6 kg (SD, 9.5 kg) by 3 months, 34.2.kg (SD, 20.1 kg) by 12 months and 39.9 kg (SD, 31.4 kg) by 24 months (P < 0.001). Body mass index (BMI) decreased from a preoperative mean of 48.2 kg/m<sup>2</sup> (SD, 9.5 kg/m<sup>2</sup>) to 35.7 kg/m<sup>2</sup> (SD, 7.7 kg/m<sup>2</sup>) by 24 months (P < 0.001). Full resolution of comorbid conditions by 18 months (P < 0.001) was achieved by almost half of those with baseline T2DM, nearly two-thirds with HTN and three-quarters of those with OSA, with continued improvements beyond 24 months. Conclusions: Bariatric surgery performed in the public sector is efficacious in the treatment of obese patients with comorbid conditions. Our findings parallel similar studies suggesting that there is equal benefit in publicly funded and privately performed procedures. This study highlights that obese patients reliant on public health care maintain sufficient intrinsic motivation in the absence of payment and supposed value-driven incentive. Improved access to bariatric surgery in the public sector can justifiably reduce the health inequities for those most in need

Tests of the fundamental symmetries in eta meson decays

Patterns of chiral symmetry violation and tests of the conservation of the fundamental C, P and CP symmetries are key physics issues in studies of the pi0, eta and eta' meson decays. These tests include searches for rare or forbidden decays and searches for asymmetries among the decay products in the not-so-rare decays. Some examples for the rare decays are eta-->2pi, eta-->4pi0 (CP tests), decays into an odd number of photons (e.g., eta-->3g) and the decay eta-->pi0e+e- (C tests). The experimental studies of the pi0, eta and eta' meson decays are carried out at four European accelerator research facilities: KLOE/KLOE-2 at DAFNE (Frascati), Crystal Ball at MAMI (Mainz), WASA at COSY (J\"ulich), Crystal Barrel at ELSA (Bonn).Comment: 9 pages, 2 figures, proceedings of Symposium on Prospects in the Physics of Discrete Symmetries, DISCRETE 2010, 6 - 11 December, Rome; v2: added reference

Hubble Space Telescope Grism Spectroscopy of Extreme Starbursts Across Cosmic Time: The Role of Dwarf Galaxies in the Star Formation History of the Universe

Near infrared slitless spectroscopy with the Wide Field Camera 3, onboard the Hubble Space Telescope, offers a unique opportunity to study low-mass galaxy populations at high-redshift ($z\sim$1-2). While most high$-z$ surveys are biased towards massive galaxies, we are able to select sources via their emission lines that have very-faint continua. We investigate the star formation rate (SFR)-stellar mass ($M_{\star}$) relation for about 1000 emission-line galaxies identified over a wide redshift range of $0.3 \lesssim z \lesssim 2.3$. We use the H$_{\alpha}$ emission as an accurate SFR indicator and correct the broadband photometry for the strong nebular contribution to derive accurate stellar masses down to $M_{\star} \sim 10^{7} M_{\odot}$. We focus here on a subsample of galaxies that show extremely strong emission lines (EELGs) with rest-frame equivalent widths ranging from 200 to 1500 \AA. This population consists of outliers to the normal SFR-$M_{\star}$ sequence with much higher specific SFRs ($> 10$ Gyr$^{-1}$). While on-sequence galaxies follow a continuous star formation process, EELGs are thought to be caught during an extreme burst of star formation that can double their stellar mass in less than $100$ Myr. The contribution of starbursts to the total star formation density appears to be larger than what has been reported for more massive galaxies in previous studies. In the complete mass range $8.2 <$ log($M_{\star}/M_{\odot}$) $< 10$ and a SFR lower completeness limit of about 2 $M_{\odot}$ yr$^{-1}$ (10 $M_{\odot}$ yr$^{-1}$) at $z\sim1$ ($z \sim 2$), we find that starbursts having EW$_{rest}$(H$_{\alpha}$)$>$ 300, 200, and 100 A contribute up to $\sim13$, 18, and 34 %, respectively, to the total SFR of emission-line selected sample at $z\sim1-2$. The comparison with samples of massive galaxies shows an increase in the contribution of starbursts towards lower masses.Comment: 11 pages, 6 figures. The Astrophysical Journal, in pres

Pediatric diabetes consortium T1D New Onset ( NeOn ) study: clinical outcomes during the first year following diagnosis

Objective There have been few prospective, multicenter studies investigating the natural history of type 1 diabetes ( T1D ) from the time of diagnosis. The objective of this report from the Pediatric Diabetes Consortium ( PDC ) T1D New Onset ( NeOn ) study was to assess the natural history and clinical outcomes in children during the first year after diagnosis of T1D . Research design and methods: Clinical measures from the first year following diagnosis were analyzed for 857 participants (mean age 9.1 yr, 51% female, 66% non‐Hispanic White) not participating in an intervention study who had a HbA1c result at 12 months. Results Mean HbA1c ± SD was 102 ± 25 mmol/mol (11.4 ± 2.3%) at diagnosis, 55 ± 12 mmol/mol (7.2 ± 1.1%) at 3 months, 56 ± 15 mmol/mol (7.3 ± 1.3%) at 6 months and 62 ± 16 mmol/mol (7.8 ± 1.5%) at 12 months from diagnosis. A severe hypoglycemic ( SH ) event occurred in 31 (4%) participants (44 events, 5.2 events per 100 person‐years). Diabetic ketoacidosis ( DKA ) not including diagnosis occurred in 10 (1%) participants (13 events, 1.5 events per 100 person‐years). Conclusions After onset of T1D , mean HbA1c reaches its nadir at 3–6 months with a gradual increase through 12 months. SH and DKA are uncommon but still occur during the first year with T1D . Data from large cohorts, such as the PDC T1D NeOn study, provide important insights into the course of T1D during the first year following diagnosis, which will help to inform the development of models to target future interventions.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/107374/1/pedi12068.pd